Deep search
Search
Copilot
Images
Videos
Maps
News
Shopping
More
Flights
Travel
Hotels
Real Estate
Notebook
Top stories
Sports
U.S.
2024 Election
Local
World
Science
Technology
Entertainment
Business
More
Politics
Any time
Past hour
Past 24 hours
Past 7 days
Past 30 days
Best match
Most recent
Alzheimer's, Lilly
Gradual dosing of Lilly Alzheimer's drug cuts brain-swelling risk, study finds
Starting on a more gradual dosing schedule of Eli Lilly's Alzheimer's drug Kisunla cut the percentage of patients experiencing potentially serious brain swelling, according to interim results of a late-stage trial presented at a medical meeting on Tuesday.
Eli Lilly says modified dosing of its Alzheimer’s drug may be safer
A change in the dosing regimen of Eli Lilly’s Alzheimer’s drug Kisunla resulted in a lower rate of brain swelling among patients in a clinical trial, new data show.
Modified dosing regimen of Eli Lilly's Alzheimer's drug leads to significant reduction in brain swelling
A small tweak in the dosing regimen of Eli Lilly’s Alzheimer’s disease drug Kisunla has reduced brain swelling of patients in a trial, the company said on Tuesday.
Eli Lilly says Donanemab redudced ARIA-E in early Alzheimer’s patients
Eli Lilly (LLY) announced “positive results” from the TRAILBLAZER-ALZ 6 Phase 3b study, showing a reduction in amyloid-related
UK approves Lilly's Alzheimer's drug, but deemed 'too expensive' for wide use
Eli Lilly's treatment for early Alzheimer's was deemed too expensive for wide use by UK's cost-effectiveness body on Wednesday, signalling that patients are unlikely to get access following approval by the country's medicines regulator.
England’s Drug-Cost Watchdog Rejects Eli Lilly’s Alzheimer’s Drug
England’s drug-cost regulator rejected Eli Lilly’s Alzheimer’s drug for use in the country’s public health system, marking the second time a treatment for the disease has been deemed too costly.The U.
Eli Lilly Alzheimer’s Drug Rejected for NHS Use in England
Eli Lilly & Co’s Alzheimer’s drug won’t be made available for patients using England’s National Health Service, after the drug cost regulator deemed its benefits were too small to justify the price.
1d
on MSN
Eli Lilly's Latest Setback Could Portend an Unexpected Headwind for the Stock
As grim as the likely loss of the U.K. market for the drug may be, Lilly is far from helpless, and the damage, while notable, might not actually drag on its growth by a noticeable amount if its ...
MM&M
1d
AbbVie takes bet on new Alzheimer’s drug in $1.4 billion acquisition of Aliada Therapeutics
The purchase is the latest in a slew of efforts to invest in its neuroscience portfolio as Humira faces generic competition.
FierceBiotech
1d
AbbVie inks $1.4B Aliada buyout to land ex-J&J Alzheimer’s drug
AbbVie has agreed to pay $1.4 billion to buy Aliada Therapeutics. The acquisition will give AbbVie control of an Alzheimer’s ...
33m
Lilly reports Q3 2024 financial results highlighted by strong volume-driven revenue growth from New Products
Revenue in Q3 2024 increased 20%, driven by volume growth from Mounjaro and Zepbound, partially offset by $1.42 billion of ...
19h
Lilly Alzheimer’s Dosing Tweak Cuts Brain Swelling Risk in Study
Eli Lilly & Co. said that a small change in dosing its Alzheimer’s drug Kisunla cut patients’ rate of brain-swelling side ...
pharmaphorum
3h
Lilly touts new Kisunla regimen that reduces side effects
Eli Lilly says a new starting dose regimen for its Alzheimer's disease therapy Kisunla reduces the risk of side effects that ...
Some results have been hidden because they may be inaccessible to you
Show inaccessible results
Feedback